SlideShare a Scribd company logo
1 of 1
Download to read offline
Examination of the Structure-Activity Relationships of Inhibitors of Plasminogen Activator Inhibitor-1
                                                                                                        Structure-                                                              Inhibitor-
                                                                                  Karen L. Sanders,1 Hasina Saraha,1 Mark Warnock,2 Jacqueline M. Cale,2 Daniel A. Lawrence,2 and Cory D. Emal1*; (1) Chemistry
                                                                                  Department, Eastern Michigan University, Ypsilanti, 48197; (2) Department of Internal Medicine, University of Michigan Medical
                                                                                  School, Ann Arbor, MI, 48109

                             Introduction/Background                                                                   Common Structural Themes                                                                                                 Inhibition Results
 The inhibition of plasminogen activator-inhibitor-1 (PAI-1) is                                      Many of the compounds displaying PAI-1 inhibition contain gallate or              Effect of modifying the gallate to a protocatechuate on PAI-1 inhibition:
 anticipated to increase our understanding of various human ailments                                 digallate groups. The focus of our research has been centered on the
 including diabetes, stroke, and atherosclerosis, for which high levels of                           structure-activity relationship of different configurations of polyphenols.
 PAI-1 have been associated.(1) PAI-1 prevents certain serine proteases                              This includes the manipulation of the carbamate handle and the number and
 from cleaving peptide bonds and thus is able to regulate various cellular                           position of the hydroxyl groups on the inhibitory molecules.                                                                                                                                                                   IC50 = 0.105 µm

 processes such as controlling the levels of other intracellular proteins,                                                                                                                                                                                                     IC50 = 0.062 µm

 such as tissue-type plasminogen activator (tPA) and urokinase-type                                                                                                                    IC50 = 0.104 µm

 plasminogen activator (uPA).(2)                                                                      Goal: to determine the effect of manipulating the carbamate handle and
                                                                                                      the number and position of the hydroxyl groups on the gallate core.
                                                                                                                                                                                                                                                                                                                                  IC50 = 0.029 µm


                                                                                                                                                                                       IC50 = 9.6 µm                                       IC50 = 0.048 µm

                                                                                                                             Design and Synthesis
                                                                                                                                                                                       Effect of manipulating the carbamate handle on PAI-1 inhibition:
                                                                                                      The focus of the reactions depicted in Scheme 1 is the production of              IC50 = 4.75 µm                                                       IC50 = 0.159 µm
                                                                                                                                                                                                                                                                                                                 IC50 = 4.69 µm
                                                                                                      compounds that investigate the effect of manipulating the carbamate handle
  Fibrinolysis: Green arrows indicate a                                                               on either a gallate or protocatechuate coupled species. In concert, the effect
  stimulatory effect, and red arrows
  indicate an inhibitory effect.
                                                                                                      on inhibition which the change in either the number or position of the
                                                                                                      hydroxyl groups that compose the gallate core was examined. A series of
                                                                                                      five-six reactions are required to synthesize the desired compounds. These
                                                                                                      reactions were repeated as necessary using different attachments. The last
Therefore, the goal of this research is to inhibit the inhibitor of fibrinolysis,                     step which entailed the removal of the benzyl protecting groups utilized
                                                                                                                                                                                                                       IC50 = 0.02 µm
the process which leads to the break down of blood clots.                                             Pd/C 10%. Attempts were made to remove these protecting groups with an                                                                                                   IC50 = 0.0108 µm                                   IC50 = 0.022 µm

                                                                                                      encapsulated version, Pd Encat 30 Palladium Acetate Microencapsulated in
The complexity of the PAI-1 structure has the potential to possess several
                                                                                                      Polyurea Matrix 0.4 mmol Pd/g. It was done with the aim of eliminating
binding sites to a wide variety of inhibitory molecules. Development of
                                                                                                      the highly toxic palladium from in vivo studies.(4)
therapeutic agents that act as selective inhibitors of PAI-1 may provide an
approach to treat these ailments. Recent reports have noticed inhibitive
properties in furan-2-one and pyrrolin-2-one derivatives.(3) However,                                Scheme 1: Synthesis of differing PAI-1 inhibitory molecules                                                                                                                                                                    IC50 = ? µm
                                                                                                                                                                                                                          IC50 = ? µm                                               IC50 = 0.027 µm
these known accounts have reported the synthesis of inhibitors that bind to
PAI-1 with a low affinity and fail to inhibit PAI-1 when vitronectin, a
cofactor of PAI-1 is present.                                                                                                                                                                                                                            Conclusion

                                                                                                                                                                                         Activity towards PAI-1 is very sensitive to the identity of the
                                                                                                                                                                                         carbamate handle. Carbamate handles which are composed of electron-rich
                                                                                                                                                                                         Species result in a increased inhibition of PAI-1. The modification of the gallate
                                                               IC50 = 9.6 µm                                                                                                             core to a protocatechuate results in a positive increase in the inhibition of the
                                                                                                                                                                                         serpin.
                                                          A furan-2-one/pyrrolin-2-one derivative.

A high-throughput screen was conducted by Daniel Lawrence and
                                                                                                                                                                                                                                             Future Directions
                                                                                                                                                                                       - Test the inhibitory effect of electronically larger species attachments.
coworkers at the University of Michigan against a large library of a variety                                                                                                           - Synthesize inhibitors with asymmetric gallate attachments.
of organic compounds. Some of these compounds proved to be effective                                                                                                                   - Incorporate R-NH2 attachments.
PAI-1 inhibitors. Many of these compounds contain gallate or digallate
groups. Similar compounds containing related phenolic structures did not                                                                                                                                                                  Acknowledgements
show inhibitory activity versus PAI-1. Molecules were synthesized                                                                                                                      - The remaining members of the Emal and Lawrence research groups
containing varying numbers of gallates which proved to be effective PAI-1
inhibitors.                                                                                                                                                                            Funding from:
                                                                                                                                                                                       - Eastern Michigan University
                         O                 O
                                                                                                                                                                                       - Camille and Henry Dreyfus Foundation
         HO                                          OH
                             O         O                                                                                                                                               - National Institutes of Health
         HO
                                  O    O
                                                     OH
                                                                                                                                                                                                                                                      References
                    OH                          OH                                                                                                                                        1.) Ren, Y., Himmeldirk, K., Chen, X. J. Med. Chem. 2006, 49, 2829-2837.
                                                                                                                                                                                          2.) Wang et al. Biochemistry. 1996, 35 (51), 16443-16448.
                                                                                                                                                                                          3.) Miyazaki, H.; Ogiku, T.; Hiroshi, S.; Moritani, Y.; Ohtanl, A. Chem. Pharm. Bull. 2009, 57 (9) 979-985.
                                                                                                                                                                                          4.) Cale, J. M.; Li, S.; Warnock, M.; Su, E. J.; North, P. R.; Sanders, K. L.; Puscau, M. M.; Emal, C. D.; Lawrence,
                             HO            OH                                       IC50 = 0.37 µm                                                                                            D. A. Characterization of a Novel Class of Polyphenolic Inhibitors of Plasminogen Activator Inhibitor-1. J.
  IC50 = 0.025 µm                                                                                                                                                                             Bio. Chem. 2010 In Press
                                      OH

More Related Content

What's hot

Pharmacodynamics By Dr Debasish Pradhan
Pharmacodynamics By Dr Debasish PradhanPharmacodynamics By Dr Debasish Pradhan
Pharmacodynamics By Dr Debasish Pradhangundu333pappu
 
jz300725d_Ramirez_Presentation
jz300725d_Ramirez_Presentationjz300725d_Ramirez_Presentation
jz300725d_Ramirez_Presentationjpcoffice
 
Research Poster 2009
Research Poster 2009Research Poster 2009
Research Poster 2009guestf70f7f
 
Screening Assays For Gpc Rs 3
Screening Assays For Gpc Rs 3Screening Assays For Gpc Rs 3
Screening Assays For Gpc Rs 3Shirley Pullan
 
20120615_Granatum_COST_v2
20120615_Granatum_COST_v220120615_Granatum_COST_v2
20120615_Granatum_COST_v2Christos Kannas
 
Sigma Xi - EKS95460- ekta sharma
Sigma Xi - EKS95460- ekta sharmaSigma Xi - EKS95460- ekta sharma
Sigma Xi - EKS95460- ekta sharmaerku2210
 
Determination of the Gas-Phase Acidities of the Cysteine-Polyglycine Peptides
Determination of the Gas-Phase Acidities of the Cysteine-Polyglycine PeptidesDetermination of the Gas-Phase Acidities of the Cysteine-Polyglycine Peptides
Determination of the Gas-Phase Acidities of the Cysteine-Polyglycine Peptideskiran_uoh
 
Rapidfireslide jessschlosser 1
Rapidfireslide jessschlosser 1Rapidfireslide jessschlosser 1
Rapidfireslide jessschlosser 1jessschlosser
 
Structure analysis of protein
Structure analysis of proteinStructure analysis of protein
Structure analysis of proteinKAUSHAL SAHU
 
Chemical protein engineering synthetic and semisynthetic
Chemical protein engineering synthetic and semisyntheticChemical protein engineering synthetic and semisynthetic
Chemical protein engineering synthetic and semisyntheticAli Hatami
 
La0150 b arthrex biocomposite white paper - ib
La0150 b   arthrex biocomposite white paper - ibLa0150 b   arthrex biocomposite white paper - ib
La0150 b arthrex biocomposite white paper - ibdrnaula
 
Website conjugates v4
Website   conjugates v4Website   conjugates v4
Website conjugates v4Amunix
 
Benzodiazopines SAR by dr. khalid hussain
Benzodiazopines SAR by dr. khalid hussainBenzodiazopines SAR by dr. khalid hussain
Benzodiazopines SAR by dr. khalid hussainZeeshan Naseer
 
Introduction to XTEN v1
Introduction to XTEN v1Introduction to XTEN v1
Introduction to XTEN v1Amunix
 
Adrenergic and anti-adrenergic agents
Adrenergic and anti-adrenergic agentsAdrenergic and anti-adrenergic agents
Adrenergic and anti-adrenergic agentsTanviGoel25
 

What's hot (20)

Bu32451456
Bu32451456Bu32451456
Bu32451456
 
Pharmacodynamics By Dr Debasish Pradhan
Pharmacodynamics By Dr Debasish PradhanPharmacodynamics By Dr Debasish Pradhan
Pharmacodynamics By Dr Debasish Pradhan
 
jz300725d_Ramirez_Presentation
jz300725d_Ramirez_Presentationjz300725d_Ramirez_Presentation
jz300725d_Ramirez_Presentation
 
Research Poster 2009
Research Poster 2009Research Poster 2009
Research Poster 2009
 
Screening Assays For Gpc Rs 3
Screening Assays For Gpc Rs 3Screening Assays For Gpc Rs 3
Screening Assays For Gpc Rs 3
 
20120615_Granatum_COST_v2
20120615_Granatum_COST_v220120615_Granatum_COST_v2
20120615_Granatum_COST_v2
 
Sigma Xi - EKS95460- ekta sharma
Sigma Xi - EKS95460- ekta sharmaSigma Xi - EKS95460- ekta sharma
Sigma Xi - EKS95460- ekta sharma
 
Determination of the Gas-Phase Acidities of the Cysteine-Polyglycine Peptides
Determination of the Gas-Phase Acidities of the Cysteine-Polyglycine PeptidesDetermination of the Gas-Phase Acidities of the Cysteine-Polyglycine Peptides
Determination of the Gas-Phase Acidities of the Cysteine-Polyglycine Peptides
 
Otz poster 12.12
Otz poster 12.12Otz poster 12.12
Otz poster 12.12
 
Rapidfireslide jessschlosser 1
Rapidfireslide jessschlosser 1Rapidfireslide jessschlosser 1
Rapidfireslide jessschlosser 1
 
Acs2006 Mrm
Acs2006 MrmAcs2006 Mrm
Acs2006 Mrm
 
Structure analysis of protein
Structure analysis of proteinStructure analysis of protein
Structure analysis of protein
 
Chemical protein engineering synthetic and semisynthetic
Chemical protein engineering synthetic and semisyntheticChemical protein engineering synthetic and semisynthetic
Chemical protein engineering synthetic and semisynthetic
 
Kate_Poster
Kate_PosterKate_Poster
Kate_Poster
 
La0150 b arthrex biocomposite white paper - ib
La0150 b   arthrex biocomposite white paper - ibLa0150 b   arthrex biocomposite white paper - ib
La0150 b arthrex biocomposite white paper - ib
 
Peptidomimetics
PeptidomimeticsPeptidomimetics
Peptidomimetics
 
Website conjugates v4
Website   conjugates v4Website   conjugates v4
Website conjugates v4
 
Benzodiazopines SAR by dr. khalid hussain
Benzodiazopines SAR by dr. khalid hussainBenzodiazopines SAR by dr. khalid hussain
Benzodiazopines SAR by dr. khalid hussain
 
Introduction to XTEN v1
Introduction to XTEN v1Introduction to XTEN v1
Introduction to XTEN v1
 
Adrenergic and anti-adrenergic agents
Adrenergic and anti-adrenergic agentsAdrenergic and anti-adrenergic agents
Adrenergic and anti-adrenergic agents
 

Viewers also liked

Pai 1 inhibitors
Pai 1 inhibitorsPai 1 inhibitors
Pai 1 inhibitorsHitesh Soni
 
TISSUE RENIN ANGIOTENSIN SYSTEM
TISSUE RENIN ANGIOTENSIN SYSTEMTISSUE RENIN ANGIOTENSIN SYSTEM
TISSUE RENIN ANGIOTENSIN SYSTEMRamachandra Barik
 
My phD work Title "INVESTIGATION INTO THE MECHANISM OF ACTION OF CARDIOVASCUL...
My phD work Title "INVESTIGATION INTO THE MECHANISM OF ACTION OF CARDIOVASCUL...My phD work Title "INVESTIGATION INTO THE MECHANISM OF ACTION OF CARDIOVASCUL...
My phD work Title "INVESTIGATION INTO THE MECHANISM OF ACTION OF CARDIOVASCUL...Hitesh Soni
 
Renin angiotensin aldosterone- Updates
Renin angiotensin aldosterone-   UpdatesRenin angiotensin aldosterone-   Updates
Renin angiotensin aldosterone- UpdatesRamachandra Barik
 
Renin-Angiotensin Aldosterone system
Renin-Angiotensin Aldosterone systemRenin-Angiotensin Aldosterone system
Renin-Angiotensin Aldosterone system軒名 林
 
Renin angiotensin aldosterone system
Renin angiotensin aldosterone systemRenin angiotensin aldosterone system
Renin angiotensin aldosterone systemSimon Ngunjiri
 
Fibrinolytics & antiplatelets
Fibrinolytics & antiplateletsFibrinolytics & antiplatelets
Fibrinolytics & antiplateletsNaser Tadvi
 
Renin angiotensin system & drugs
Renin angiotensin system & drugsRenin angiotensin system & drugs
Renin angiotensin system & drugsSurya Prajapat
 
Myocardial Infarction
Myocardial InfarctionMyocardial Infarction
Myocardial Infarctiongdriven
 
Myocardial infarction
Myocardial infarctionMyocardial infarction
Myocardial infarctionadolescent4u
 
Acute Myocardial Infarction
Acute Myocardial InfarctionAcute Myocardial Infarction
Acute Myocardial InfarctionAnwar Siddiqui
 
MYOCARDIAL INFARCTION-MANAGEMENT
MYOCARDIAL INFARCTION-MANAGEMENTMYOCARDIAL INFARCTION-MANAGEMENT
MYOCARDIAL INFARCTION-MANAGEMENTshrinathraman
 
Myocardial Infarction
Myocardial InfarctionMyocardial Infarction
Myocardial InfarctionReynel Dan
 

Viewers also liked (20)

Pai 1 inhibitors
Pai 1 inhibitorsPai 1 inhibitors
Pai 1 inhibitors
 
TISSUE RENIN ANGIOTENSIN SYSTEM
TISSUE RENIN ANGIOTENSIN SYSTEMTISSUE RENIN ANGIOTENSIN SYSTEM
TISSUE RENIN ANGIOTENSIN SYSTEM
 
Histamine and antihistaminics
Histamine and antihistaminicsHistamine and antihistaminics
Histamine and antihistaminics
 
My phD work Title "INVESTIGATION INTO THE MECHANISM OF ACTION OF CARDIOVASCUL...
My phD work Title "INVESTIGATION INTO THE MECHANISM OF ACTION OF CARDIOVASCUL...My phD work Title "INVESTIGATION INTO THE MECHANISM OF ACTION OF CARDIOVASCUL...
My phD work Title "INVESTIGATION INTO THE MECHANISM OF ACTION OF CARDIOVASCUL...
 
Renin angiotensin aldosterone- Updates
Renin angiotensin aldosterone-   UpdatesRenin angiotensin aldosterone-   Updates
Renin angiotensin aldosterone- Updates
 
Renin-Angiotensin Aldosterone system
Renin-Angiotensin Aldosterone systemRenin-Angiotensin Aldosterone system
Renin-Angiotensin Aldosterone system
 
Renin angiotensin aldosterone system
Renin angiotensin aldosterone systemRenin angiotensin aldosterone system
Renin angiotensin aldosterone system
 
Fibrinolytics & antiplatelets
Fibrinolytics & antiplateletsFibrinolytics & antiplatelets
Fibrinolytics & antiplatelets
 
Drugs affecting renin-angiotensin system
Drugs affecting renin-angiotensin systemDrugs affecting renin-angiotensin system
Drugs affecting renin-angiotensin system
 
Renin angiotensin system & drugs
Renin angiotensin system & drugsRenin angiotensin system & drugs
Renin angiotensin system & drugs
 
Thrombolytics ppt
Thrombolytics pptThrombolytics ppt
Thrombolytics ppt
 
Fibrinolytic agents
Fibrinolytic agentsFibrinolytic agents
Fibrinolytic agents
 
Myocardial Infarction
Myocardial InfarctionMyocardial Infarction
Myocardial Infarction
 
Metabolic syndrome
Metabolic syndromeMetabolic syndrome
Metabolic syndrome
 
Acute Myocardial infarction
Acute Myocardial infarctionAcute Myocardial infarction
Acute Myocardial infarction
 
Myocardial infarction
Myocardial infarctionMyocardial infarction
Myocardial infarction
 
Acute Myocardial Infarction
Acute Myocardial InfarctionAcute Myocardial Infarction
Acute Myocardial Infarction
 
MYOCARDIAL INFARCTION-MANAGEMENT
MYOCARDIAL INFARCTION-MANAGEMENTMYOCARDIAL INFARCTION-MANAGEMENT
MYOCARDIAL INFARCTION-MANAGEMENT
 
Myocardial Infarction
Myocardial InfarctionMyocardial Infarction
Myocardial Infarction
 
Myocardial Infarction
Myocardial InfarctionMyocardial Infarction
Myocardial Infarction
 

Similar to Structure-Activity Relationships of PAI-1 Inhibitors

The Role Of G Protein Coupled Receptorss
The Role Of G Protein Coupled ReceptorssThe Role Of G Protein Coupled Receptorss
The Role Of G Protein Coupled ReceptorssAngela Hays
 
Optimization of Bacillus Subtilis Natto Immobilization Process on Alginate – ...
Optimization of Bacillus Subtilis Natto Immobilization Process on Alginate – ...Optimization of Bacillus Subtilis Natto Immobilization Process on Alginate – ...
Optimization of Bacillus Subtilis Natto Immobilization Process on Alginate – ...inventionjournals
 
Optimization of Bacillus Subtilis Natto Immobilization Process on Alginate – ...
Optimization of Bacillus Subtilis Natto Immobilization Process on Alginate – ...Optimization of Bacillus Subtilis Natto Immobilization Process on Alginate – ...
Optimization of Bacillus Subtilis Natto Immobilization Process on Alginate – ...inventionjournals
 
2009 Convegno Malattie Rare Rastaldi [23 01]
2009 Convegno Malattie Rare Rastaldi [23 01]2009 Convegno Malattie Rare Rastaldi [23 01]
2009 Convegno Malattie Rare Rastaldi [23 01]cmid
 
Antibiotics & mechanisms of actions
Antibiotics & mechanisms of actionsAntibiotics & mechanisms of actions
Antibiotics & mechanisms of actionsabiola adeosun
 
antibioticsmechanismsofactions-150428084652-conversion-gate02.pdf
antibioticsmechanismsofactions-150428084652-conversion-gate02.pdfantibioticsmechanismsofactions-150428084652-conversion-gate02.pdf
antibioticsmechanismsofactions-150428084652-conversion-gate02.pdfBucky10
 
ACG-128-MOA-Acetogenins-Bullatacin-Cortes-ES-1994
ACG-128-MOA-Acetogenins-Bullatacin-Cortes-ES-1994ACG-128-MOA-Acetogenins-Bullatacin-Cortes-ES-1994
ACG-128-MOA-Acetogenins-Bullatacin-Cortes-ES-1994Ben Rockefeller
 
Poster - RNAi Therapeutics by Silence Therapeutics - American Society of Cli...
Poster - RNAi Therapeutics by Silence Therapeutics -  American Society of Cli...Poster - RNAi Therapeutics by Silence Therapeutics -  American Society of Cli...
Poster - RNAi Therapeutics by Silence Therapeutics - American Society of Cli...Silence Therapeutics
 
Zwiegers can 2012
Zwiegers can 2012Zwiegers can 2012
Zwiegers can 2012zwiegers
 
Protein Chromatography
Protein ChromatographyProtein Chromatography
Protein ChromatographyNicole Gomez
 
Structure activity relationship 6
Structure activity relationship 6Structure activity relationship 6
Structure activity relationship 6Abdul Samad
 
lehninger(sixth edition) Ch 03: Amino acids, peptides and proteins
lehninger(sixth edition) Ch 03: Amino acids, peptides and proteinslehninger(sixth edition) Ch 03: Amino acids, peptides and proteins
lehninger(sixth edition) Ch 03: Amino acids, peptides and proteinskrupal parmar
 
Rubisco Lab Report
Rubisco Lab ReportRubisco Lab Report
Rubisco Lab ReportTammy Lacy
 

Similar to Structure-Activity Relationships of PAI-1 Inhibitors (14)

The Role Of G Protein Coupled Receptorss
The Role Of G Protein Coupled ReceptorssThe Role Of G Protein Coupled Receptorss
The Role Of G Protein Coupled Receptorss
 
Optimization of Bacillus Subtilis Natto Immobilization Process on Alginate – ...
Optimization of Bacillus Subtilis Natto Immobilization Process on Alginate – ...Optimization of Bacillus Subtilis Natto Immobilization Process on Alginate – ...
Optimization of Bacillus Subtilis Natto Immobilization Process on Alginate – ...
 
Optimization of Bacillus Subtilis Natto Immobilization Process on Alginate – ...
Optimization of Bacillus Subtilis Natto Immobilization Process on Alginate – ...Optimization of Bacillus Subtilis Natto Immobilization Process on Alginate – ...
Optimization of Bacillus Subtilis Natto Immobilization Process on Alginate – ...
 
2009 Convegno Malattie Rare Rastaldi [23 01]
2009 Convegno Malattie Rare Rastaldi [23 01]2009 Convegno Malattie Rare Rastaldi [23 01]
2009 Convegno Malattie Rare Rastaldi [23 01]
 
Antibiotics & mechanisms of actions
Antibiotics & mechanisms of actionsAntibiotics & mechanisms of actions
Antibiotics & mechanisms of actions
 
antibioticsmechanismsofactions-150428084652-conversion-gate02.pdf
antibioticsmechanismsofactions-150428084652-conversion-gate02.pdfantibioticsmechanismsofactions-150428084652-conversion-gate02.pdf
antibioticsmechanismsofactions-150428084652-conversion-gate02.pdf
 
ACG-128-MOA-Acetogenins-Bullatacin-Cortes-ES-1994
ACG-128-MOA-Acetogenins-Bullatacin-Cortes-ES-1994ACG-128-MOA-Acetogenins-Bullatacin-Cortes-ES-1994
ACG-128-MOA-Acetogenins-Bullatacin-Cortes-ES-1994
 
Rational Drug design
Rational Drug designRational Drug design
Rational Drug design
 
Poster - RNAi Therapeutics by Silence Therapeutics - American Society of Cli...
Poster - RNAi Therapeutics by Silence Therapeutics -  American Society of Cli...Poster - RNAi Therapeutics by Silence Therapeutics -  American Society of Cli...
Poster - RNAi Therapeutics by Silence Therapeutics - American Society of Cli...
 
Zwiegers can 2012
Zwiegers can 2012Zwiegers can 2012
Zwiegers can 2012
 
Protein Chromatography
Protein ChromatographyProtein Chromatography
Protein Chromatography
 
Structure activity relationship 6
Structure activity relationship 6Structure activity relationship 6
Structure activity relationship 6
 
lehninger(sixth edition) Ch 03: Amino acids, peptides and proteins
lehninger(sixth edition) Ch 03: Amino acids, peptides and proteinslehninger(sixth edition) Ch 03: Amino acids, peptides and proteins
lehninger(sixth edition) Ch 03: Amino acids, peptides and proteins
 
Rubisco Lab Report
Rubisco Lab ReportRubisco Lab Report
Rubisco Lab Report
 

Recently uploaded

CELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptxCELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptxJiesonDelaCerna
 
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...M56BOOKSTORE PRODUCT/SERVICE
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxpboyjonauth
 
Full Stack Web Development Course for Beginners
Full Stack Web Development Course  for BeginnersFull Stack Web Development Course  for Beginners
Full Stack Web Development Course for BeginnersSabitha Banu
 
Presiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsPresiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsanshu789521
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxSayali Powar
 
internship ppt on smartinternz platform as salesforce developer
internship ppt on smartinternz platform as salesforce developerinternship ppt on smartinternz platform as salesforce developer
internship ppt on smartinternz platform as salesforce developerunnathinaik
 
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxiammrhaywood
 
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...Marc Dusseiller Dusjagr
 
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdf
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdfFraming an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdf
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdfUjwalaBharambe
 
Roles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceRoles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceSamikshaHamane
 
Biting mechanism of poisonous snakes.pdf
Biting mechanism of poisonous snakes.pdfBiting mechanism of poisonous snakes.pdf
Biting mechanism of poisonous snakes.pdfadityarao40181
 
Interactive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationInteractive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationnomboosow
 
Alper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentAlper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentInMediaRes1
 
EPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptxEPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptxRaymartEstabillo3
 
भारत-रोम व्यापार.pptx, Indo-Roman Trade,
भारत-रोम व्यापार.pptx, Indo-Roman Trade,भारत-रोम व्यापार.pptx, Indo-Roman Trade,
भारत-रोम व्यापार.pptx, Indo-Roman Trade,Virag Sontakke
 
MARGINALIZATION (Different learners in Marginalized Group
MARGINALIZATION (Different learners in Marginalized GroupMARGINALIZATION (Different learners in Marginalized Group
MARGINALIZATION (Different learners in Marginalized GroupJonathanParaisoCruz
 
Proudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxProudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxthorishapillay1
 

Recently uploaded (20)

OS-operating systems- ch04 (Threads) ...
OS-operating systems- ch04 (Threads) ...OS-operating systems- ch04 (Threads) ...
OS-operating systems- ch04 (Threads) ...
 
CELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptxCELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptx
 
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptx
 
Full Stack Web Development Course for Beginners
Full Stack Web Development Course  for BeginnersFull Stack Web Development Course  for Beginners
Full Stack Web Development Course for Beginners
 
Presiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsPresiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha elections
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
 
internship ppt on smartinternz platform as salesforce developer
internship ppt on smartinternz platform as salesforce developerinternship ppt on smartinternz platform as salesforce developer
internship ppt on smartinternz platform as salesforce developer
 
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
 
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
 
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdf
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdfFraming an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdf
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdf
 
Roles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceRoles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in Pharmacovigilance
 
Biting mechanism of poisonous snakes.pdf
Biting mechanism of poisonous snakes.pdfBiting mechanism of poisonous snakes.pdf
Biting mechanism of poisonous snakes.pdf
 
Interactive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationInteractive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communication
 
9953330565 Low Rate Call Girls In Rohini Delhi NCR
9953330565 Low Rate Call Girls In Rohini  Delhi NCR9953330565 Low Rate Call Girls In Rohini  Delhi NCR
9953330565 Low Rate Call Girls In Rohini Delhi NCR
 
Alper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentAlper Gobel In Media Res Media Component
Alper Gobel In Media Res Media Component
 
EPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptxEPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptx
 
भारत-रोम व्यापार.pptx, Indo-Roman Trade,
भारत-रोम व्यापार.pptx, Indo-Roman Trade,भारत-रोम व्यापार.pptx, Indo-Roman Trade,
भारत-रोम व्यापार.pptx, Indo-Roman Trade,
 
MARGINALIZATION (Different learners in Marginalized Group
MARGINALIZATION (Different learners in Marginalized GroupMARGINALIZATION (Different learners in Marginalized Group
MARGINALIZATION (Different learners in Marginalized Group
 
Proudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxProudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptx
 

Structure-Activity Relationships of PAI-1 Inhibitors

  • 1. Examination of the Structure-Activity Relationships of Inhibitors of Plasminogen Activator Inhibitor-1 Structure- Inhibitor- Karen L. Sanders,1 Hasina Saraha,1 Mark Warnock,2 Jacqueline M. Cale,2 Daniel A. Lawrence,2 and Cory D. Emal1*; (1) Chemistry Department, Eastern Michigan University, Ypsilanti, 48197; (2) Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, 48109 Introduction/Background Common Structural Themes Inhibition Results The inhibition of plasminogen activator-inhibitor-1 (PAI-1) is Many of the compounds displaying PAI-1 inhibition contain gallate or Effect of modifying the gallate to a protocatechuate on PAI-1 inhibition: anticipated to increase our understanding of various human ailments digallate groups. The focus of our research has been centered on the including diabetes, stroke, and atherosclerosis, for which high levels of structure-activity relationship of different configurations of polyphenols. PAI-1 have been associated.(1) PAI-1 prevents certain serine proteases This includes the manipulation of the carbamate handle and the number and from cleaving peptide bonds and thus is able to regulate various cellular position of the hydroxyl groups on the inhibitory molecules. IC50 = 0.105 µm processes such as controlling the levels of other intracellular proteins, IC50 = 0.062 µm such as tissue-type plasminogen activator (tPA) and urokinase-type IC50 = 0.104 µm plasminogen activator (uPA).(2) Goal: to determine the effect of manipulating the carbamate handle and the number and position of the hydroxyl groups on the gallate core. IC50 = 0.029 µm IC50 = 9.6 µm IC50 = 0.048 µm Design and Synthesis Effect of manipulating the carbamate handle on PAI-1 inhibition: The focus of the reactions depicted in Scheme 1 is the production of IC50 = 4.75 µm IC50 = 0.159 µm IC50 = 4.69 µm compounds that investigate the effect of manipulating the carbamate handle Fibrinolysis: Green arrows indicate a on either a gallate or protocatechuate coupled species. In concert, the effect stimulatory effect, and red arrows indicate an inhibitory effect. on inhibition which the change in either the number or position of the hydroxyl groups that compose the gallate core was examined. A series of five-six reactions are required to synthesize the desired compounds. These reactions were repeated as necessary using different attachments. The last Therefore, the goal of this research is to inhibit the inhibitor of fibrinolysis, step which entailed the removal of the benzyl protecting groups utilized IC50 = 0.02 µm the process which leads to the break down of blood clots. Pd/C 10%. Attempts were made to remove these protecting groups with an IC50 = 0.0108 µm IC50 = 0.022 µm encapsulated version, Pd Encat 30 Palladium Acetate Microencapsulated in The complexity of the PAI-1 structure has the potential to possess several Polyurea Matrix 0.4 mmol Pd/g. It was done with the aim of eliminating binding sites to a wide variety of inhibitory molecules. Development of the highly toxic palladium from in vivo studies.(4) therapeutic agents that act as selective inhibitors of PAI-1 may provide an approach to treat these ailments. Recent reports have noticed inhibitive properties in furan-2-one and pyrrolin-2-one derivatives.(3) However, Scheme 1: Synthesis of differing PAI-1 inhibitory molecules IC50 = ? µm IC50 = ? µm IC50 = 0.027 µm these known accounts have reported the synthesis of inhibitors that bind to PAI-1 with a low affinity and fail to inhibit PAI-1 when vitronectin, a cofactor of PAI-1 is present. Conclusion Activity towards PAI-1 is very sensitive to the identity of the carbamate handle. Carbamate handles which are composed of electron-rich Species result in a increased inhibition of PAI-1. The modification of the gallate IC50 = 9.6 µm core to a protocatechuate results in a positive increase in the inhibition of the serpin. A furan-2-one/pyrrolin-2-one derivative. A high-throughput screen was conducted by Daniel Lawrence and Future Directions - Test the inhibitory effect of electronically larger species attachments. coworkers at the University of Michigan against a large library of a variety - Synthesize inhibitors with asymmetric gallate attachments. of organic compounds. Some of these compounds proved to be effective - Incorporate R-NH2 attachments. PAI-1 inhibitors. Many of these compounds contain gallate or digallate groups. Similar compounds containing related phenolic structures did not Acknowledgements show inhibitory activity versus PAI-1. Molecules were synthesized - The remaining members of the Emal and Lawrence research groups containing varying numbers of gallates which proved to be effective PAI-1 inhibitors. Funding from: - Eastern Michigan University O O - Camille and Henry Dreyfus Foundation HO OH O O - National Institutes of Health HO O O OH References OH OH 1.) Ren, Y., Himmeldirk, K., Chen, X. J. Med. Chem. 2006, 49, 2829-2837. 2.) Wang et al. Biochemistry. 1996, 35 (51), 16443-16448. 3.) Miyazaki, H.; Ogiku, T.; Hiroshi, S.; Moritani, Y.; Ohtanl, A. Chem. Pharm. Bull. 2009, 57 (9) 979-985. 4.) Cale, J. M.; Li, S.; Warnock, M.; Su, E. J.; North, P. R.; Sanders, K. L.; Puscau, M. M.; Emal, C. D.; Lawrence, HO OH IC50 = 0.37 µm D. A. Characterization of a Novel Class of Polyphenolic Inhibitors of Plasminogen Activator Inhibitor-1. J. IC50 = 0.025 µm Bio. Chem. 2010 In Press OH